Friday 16 October 2026
Export CDXS’s income statement to Excel — free account
Codexis, Inc.
CDXS Healthcare Biotechnology
Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.
1.24
0.12
−8.82%
Follow CDXS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.65 | 1.89 | 2.02 | 4.16 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(21.34) | (11.25) | 7.07 | (28.59) | |
P/B ratio |
6.24 | 3.42 | 2.81 | 5.71 | |
Price to Tangible BV |
6.75 | 3.63 | 2.96 | 6.10 | |
EV/Sales |
2.37 | 1.57 | 1.47 | 3.79 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(17.71) | (6.56) | (5.34) | (3.59) | |
EV/FCF |
(15.15) | (5.56) | (4.34) | (3.26) | |
Quick Ratio |
2.66 | 4.93 | 3.51 | 3.62 | |
Current Ratio |
3.06 | 5.36 | 3.82 | 4.12 | |
Net Debt/EBITDA |
2.31 | 4.14 | (3.09) | 1.13 | |
Debt/Assets |
28.17% | 31.29% | 27.14% | 32.05% | |
Debt/Equity |
1.03 | 0.94 | 0.79 | 1.03 | |
Asset Turnover |
0.60 | 0.60 | 0.47 | 0.39 | |
Operating CF/Net income |
0.80 | 1.51 | 2.09 | 0.39 | |
Capex/Depreciation |
(0.46) | (0.09) | (0.27) | (0.10) | |
Interest Coverage |
(8.63) | (6.23) | 6.62 | (14.67) | |
Research and Development Expense of Revenue |
78.48% | 75.08% | 30.12% | 161.24% | |
Selling, General and Administrative Expense of Revenue |
73.26% | 64.13% | 28.74% | 130.42% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
10.61% | 9.37% | 5.65% | 29.22% | |
Graham Net Nets |
(0.07) | (0.04) | 0.00 | (0.04) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(15.04%) | (22.70%) | (31.90%) | (31.15%) | |
Free Cash Flow Yield |
(5.91%) | (14.95%) | (16.79%) | (28.00%) | |
Revenue per Share |
0.16 | 0.17 | 0.45 | 0.10 | |
Operating CF per Share |
(0.11) | (0.14) | 0.23 | (0.09) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.12) | (0.15) | 0.22 | (0.09) | |
Cash per Share |
0.61 | 0.72 | 0.90 | 0.66 | |
Shareholders Equity per Share |
0.36 | 0.48 | 0.58 | 0.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.36 | 0.48 | 0.58 | 0.43 | |
Free Cash Flow |
(10.53) | (13.33) | 19.57 | (7.88) | |
Working Capital |
48.41 | 64.80 | 71.50 | 57.72 | |
Capital Expenditures |
(0.88) | (0.18) | (0.52) | (0.18) | |
Net Current Asset Value |
(15.18) | (6.49) | (0.45) | (9.22) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.01 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.26 | 8.69 | 12.35 | 10.36 | |
Average Payables |
2.04 | 4.09 | 2.20 | 3.32 | |
Average Inventory |
1.77 | 1.89 | 1.81 | 2.02 | |
Average Assets |
129.15 | 129.13 | 148.40 | 136.07 | |
Average Common Equity |
44.29 | 46.43 | 58.73 | 55.97 |
Columns are period end dates